Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;4(1):62-71.
doi: 10.3978/j.issn.2078-6891.2012.053.

Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases

Yue Zhu  1 , Nader Hanna, Cherif Boutros, H Richard Alexander Jr
Affiliations

Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases

Yue Zhu et al. J Gastrointest Oncol. 2013 Mar.

Abstract

Peritoneal metastasis is a significant clinical challenge; life expectancy following diagnosis is usually very short. Surgical cytoreduction with HIPEC is being used with increasing frequency in selected patients; most outcome data have shown that prolonged median survivals can be observed in selected patients. This review summarizes the published data related to outcome and quality of life after cytoreduction and HIPEC to provide insights into its use in patients with peritoneal carcinomatosis.

Keywords: Cytoreduction surgery (CRS); Hyperthermic Intraperitoneal Chemotherapy (HIPEC); peritoneal metastases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A. Operative photograph shows a massive omental metastasis and smaller volume peritoneal metastases in a patient with a high grade appendiceal carcinoma; B. A complete CRS was possible resulting in a good quality of life for over one year after operation
Figure 2
Figure 2
Operative photograph shows diffuse small volume peritoneal metastases in a patient with malignant peritoneal mesothelioma. Note the relative sparing of the small bowel serosa which is a favorable finding; the mesenteric implants were treated primarily with argon beam electrofulguration
Figure 3
Figure 3
A. CT scan shows a patient with symptomatic ascites secondary to peritoneal mesothelioma before CRS and HIPEC; B. The patient underwent a successful CRS and HIPEC and remained asymptomatic and free of imageable disease based on CT scan for over 18 months
See this image and copyright information in PMC

References

    1. Glockzin G, Ghali N, Lang SA, et al. Peritoneal carcinomatosis. Surgical treatment, including hyperthermal intraperitoneal chemotherapy. Chirurg 2007;78:1100, 1102-6, 1108-10 - PubMed
    1. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108:1122-8 - PubMed
    1. Neumann V, Muller KM, Fischer M. Peritoneal mesothelioma--incidence and etiology. Pathologe 1999;20:169-76 - PubMed
    1. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumb in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9 - PubMed
    1. Ranpura V, Hapani S, Wu S.Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487-94 - PubMed